OncoMatch

OncoMatch/Clinical Trials/NCT05289687

Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL

Is NCT05289687 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Daratumumab / Hyaluronidase and Daratumumab / Hyaluronidase for t-cell acute lymphoblastic leukemia.

Phase 2RecruitingEastern Cooperative Oncology GroupNCT05289687Data as of Jun 2026

Treatment: Daratumumab / Hyaluronidase · Daratumumab / Hyaluronidase · Daratumumab / Hyaluronidase · Daratumumab / HyaluronidaseIn this study, the investigators are hypothesizing that daratumumab-hyaluronidase will effectively treat T-ALL in patients who have persistent or recurrent MRD following treatment with chemotherapy.

Check if I qualify

Extracted eligibility criteria

Treatments studied

Immunotherapy

Daratumumab / HyaluronidaseDaratumumab / HyaluronidaseDaratumumab / HyaluronidaseDaratumumab / Hyaluronidase

Cancer type

Acute Lymphoblastic Leukemia

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Must have received: intensive chemotherapy

must be in first or later hematologic CR or CRi after a minimum of 2 blocks of intensive chemotherapy

Lab requirements

Blood counts

ANC ≥ 750/μL; Platelets ≥ 75,000/μL

Kidney function

Creatinine ≤ 1.5 x institutional ULN or Creatinine Clearance > 30 ml/min

Liver function

Total or Direct bilirubin ≤ 2 mg/dL; AST(SGOT)/ALT(SGPT) ≤ 3.0 × institutional ULN

Cardiac function

NYHA Functional Classification class 2B or better

Absolute neutrophil count (ANC) ≥ 750/μL; Platelets ≥ 75,000/μL; Total or Direct bilirubin ≤ 2 mg/dL; AST(SGOT)/ALT(SGPT) ≤ 3.0 × institutional ULN; Creatinine ≤ 1.5 x institutional ULN or Creatinine Clearance > 30 ml/min; ... cardiac disease ... NYHA Functional Classification class 2B or better

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Northwestern · Chicago, Illinois

Showing up to 5 US sites.

See all sites on ClinicalTrials.gov →

Frequently asked questions

Is NCT05289687 currently recruiting?

Yes, this trial is currently recruiting patients.

Is prior treatment required for enrollment?

Yes. Patients must have previously received intensive chemotherapy.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify